Evidence map›Paper›PMID 24795218›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2015

What is hepcidin telling us about the natural history of cystic fibrosis?

A H Gifford

Registry-linked trialAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02188758 (Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02188758 completednot on this map

Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment Responses?

TypeobservationalSponsorDartmouth-Hitchcock Medical CenterRan2014 to 2018Enrolled20ConditionsCystic FibrosisArmsAdults - CFPE Treatment
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Early severe anemia as the first sign of cystic fibrosis.European journal of pediatrics · 2016
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

A H GiffordPulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States. Electronic address: giffora@hitchcock.org.

Funding

SYNERGY: The Dartmouth Center for clinical and Translational ScienceUL1TR001086 · NCATS · DARTMOUTH COLLEGE · PI GREEN, ALAN I · 2013 to 2017
$18.3M
SYNERGY: The Dartmouth Center for clinical and Translational ScienceKL2TR001088 · NCATS · DARTMOUTH COLLEGE · PI GREEN, ALAN I · 2013 to 2017
$3.3M
NCATS NIH HHS KL2 TR001088NCATS NIH HHS UL1 TR001086
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAge FactorsBiomarkersChildCystic FibrosisDisease ProgressionFemaleFerritinsHepcidinsHumansMalePrognosisSeverity of Illness IndexSex FactorsBiomarkersFerritinsHepcidinsCystic fibrosisHepcidin-25HypoferremiaInterleukin-6Iron

Identifiers

PMID24795218
PMCPMC4687399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.